Keywords: Alimera, Uluvien, pSivida, USA, FDA, Macular edema

Another FDA rejection for Alimera’s DME drug Iluvien

Article | 14 November 2011

Print This

Shares of US ophthalmic drug developer Alimera Sciences (Nasdaq: ALIM) plunged nearly 73% to $2 on Friday, when the company revealed that ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in